+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID03761108

Study of Linvoseltamab, a Bispecific Antibody, in Adults With Relapsed or Refractory Multiple Myeloma Evaluating Safety, Dosage, and Effectiveness

Led by Regeneron Pharmaceuticals · Updated on 2026-10-26

387

Participants Needed

40

Research Sites

11 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying linvoseltamab, a drug being evaluated for safety, best dosing, and potential effectiveness in treating adults with relapsed or refractory multiple myeloma. This study aims to understand side effects, how the drug behaves in the body, its blood levels, and its ability to treat cancer. The trial includes patients who have had multiple prior treatments and may have exhausted standard options. The study is divided into phases with different treatment approaches. Phase 1 has two parts dose escalation with intravenous IV linvoseltamab and subcutaneous SC administration. Participants may receive low or high doses of IV monotherapy or high doses with anti-interleukin-6 receptor prophylactic therapy. Phase 2 includes several cohorts receiving linvoseltamab monotherapy. The drug is administered according to the study protocol. Participants undergo evaluations to monitor safety and effects, including observation of dose-limiting toxicities within 28 days and treatment-emergent adverse events for up to 5 years. Researchers track blood levels of linvoseltamab, immune responses, objective response rates, and quality of life measures. The study includes detailed follow-up of health status and symptoms, lasting up to 5 years after treatment begins to assess long-term outcomes and safety.

CONDITIONS

Brief Title

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

Research Team

C

Clinical Trial Administrator

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here